維奈妥拉

{{Infobox drug
| image = Venetoclax.svg
| image_class = skin-invert-image
| width = 275
| alt =
| image2 = Venetoclax.png
| image_class2 = bg-transparent
| alt2 =
| caption =

| pronounce =

| tradename = 唯可來（Venclexta、Venclyxto）
| Drugs.com =
| MedlinePlus = a616028
| DailyMedID = Venetoclax
| pregnancy_AU = C
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration = 口服
| class =
| ATC_prefix = L01
| ATC_suffix = XX52
| ATC_supplemental =

| legal_AU = S4
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK = POM
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment = 。

最常見的副作用包括中性球低下、腹瀉、噁心、貧血、鼻咽感染以及疲倦。

維奈妥拉會與 蛋白結合。此蛋白質在慢性淋巴細胞白血病的癌細胞內濃度較高，能延長癌細胞在體內的存活時間，並讓它們對抗癌藥物產生抗藥性。維奈妥拉藉由結合Bcl-2並阻斷其作用，誘導癌細胞凋亡，進而減緩疾病惡化。

參考文獻